{{priceData.date}} {{priceData.time}}
{{'2025-06-22T19:35:40Z' | dateFormatFilter}}
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
{{'2025-06-22T13:00:45Z' | dateFormatFilter}}
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
{{'2025-06-20T23:38:25Z' | dateFormatFilter}}
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.